Safe to move forward vs. Hsp90

Ganetespib looking safe; Synta advances Hsp90 inhibitor for lung cancer

Based on recently reported Phase II data, Synta Pharmaceuticals Corp. thinks it has the first Hsp90 inhibitor to have both meaningful cancer activity and a clean safety profile. It plans to start a Phase IIb/III trial of ganetespib for lung cancer next quarter.

Heat shock protein 90 (Hsp90) is a molecular chaperone that helps fold, stabilize and activate various growth factors and kinases that promote tumor growth, survival and metastasis. Its central role in a wide variety of oncogenic processes has made it a popular target for small molecule drug developers.

But several of the

Read the full 935 word article

How to gain access

Continue reading with a
two-week free trial.